Thyroid function and ultrasonically determined thyroid size in patients receiving long-term lithium treatment

Area of Science:

• Endocrinology
• Psychiatry
• Pharmacology

Background:

• Lithium is a common treatment for manic-depressive illness.
• Thyroid dysfunction is a potential side effect of lithium therapy.
• The prevalence and mechanisms of lithium-induced thyroid changes require further investigation.

Purpose of the Study:

• To investigate thyroid function in manic-depressive patients undergoing lithium treatment.
• To assess the relationship between lithium treatment duration and thyroid abnormalities.
• To explore potential contributing factors such as smoking and autoimmunity.

Main Methods:

• Study included 100 manic-depressive patients.
• Assessed goiter prevalence based on lithium treatment history.
• Utilized ultrasonography for thyroid volume measurement.
• Monitored serum thyrotropin levels and thyroid autoimmunity markers.

Main Results:

• Goiter was significantly more common in patients treated with lithium (44-50%) versus no lithium (16%).
• Smoking was a significant factor in thyroid size and goiter.
• In non-smokers, thyroid volume correlated with lithium treatment duration.
• Hypothyroidism (subclinical or overt) increased with lithium treatment duration (4% to 21%).
• Most patients had normal thyrotropin and no autoimmunity, suggesting direct lithium effect.

Conclusions:

• Long-term lithium treatment is associated with increased goiter and thyroid volume in manic-depressive patients.
• Lithium may directly impact the thyroid gland, independent of autoimmunity or significant thyrotropin elevation.
• Further research is needed to elucidate the direct mechanisms of lithium-induced thyroid changes.